A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

This study is comparing a new drug called QLS32015 on its own against standard two-drug combination treatments (pomalidomide + dexamethasone or selinexor + dexamethasone) in people with multiple myeloma — a blood cancer affecting plasma cells — that has returned or stopped responding to previous treatments. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with multiple myeloma that has relapsed (come back) or is refractory (no longer responding to treatment) - You have received at least 3 prior treatment regimens, including a proteasome inhibitor, an immunomodulatory drug (like lenalidomide), and an anti-CD38 antibody (like daratumumab) - You have measurable levels of myeloma in your blood or urine **You may NOT be eligible if...** - You have had fewer than 3 prior lines of therapy - You have significant heart, liver, or kidney disease - You are allergic to any of the study medications - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.